If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
=== Concentration measurement === The basic principle behind the TDLAS technique is simple. The focus here is on a single absorption line in the absorption spectrum of a particular species of interest. To start, the wavelength of a diode laser is tuned over a particular absorption line of interest and the intensity of the transmitted radiation is measured. The transmitted intensity can be related to the concentration of the species present by the Beer-Lambert law, which states that when a radiation of wavenumber
In 2018, the FDA approved the Dexcom G6 for use as a stand-alone CGM, and for integration with compatible insulin pumps, making it the first continuous glucose monitor capable of direct integration with insulin pumps. The G6 was also the first CGM to operate without the need for calibrations, removing the requirement for routine fingerstick blood tests. However, actual blood glucose levels can differ from the levels reported by the CGM. The difference is primarily due to the location of the Dexcom sensor in the subcutaneous space. The sugar level there lags behind the actual changes in the bloodstream. The device retained compatibility with Dexcom's existing mobile applications, including Dexcom Share, which allows users to share glucose data with others, and Dexcom Clarity, which provides long-term trend analysis and reports. As of 2025, the Dexcom G6 remains available. In addition, while previous Dexcom CGMs were compatible only with Tandem insulin pumps, the G6 expanded its integration to the Omnipod 5 system.
Even though the majority of plant cells have a cell wall that defines their morphology, their microfilaments can generate sufficient force to achieve a number of cellular activities, such as the cytoplasmic currents generated by the microfilaments and myosin. Actin is also involved in the movement of organelles and in cellular morphogenesis, which involve cell division as well as the elongation and differentiation of the cell. The most notable proteins associated with the actin cytoskeleton in plants include: villin, which belongs to the same family as gelsolin/severin and is able to cut microfilaments and bind actin monomers in the presence of calcium cations; fimbrin, which is able to recognize and unite actin monomers and which is involved in the formation of networks (by a different regulation process from that of animals and yeasts); formins, which are able to act as an F-actin polymerization nucleating agent; myosin, a typical molecular motor that is specific to eukaryotes and which in Arabidopsis thaliana is coded for by 17 genes in two distinct classes; CHUP1, which can bind actin and is implicated in the spatial distribution of chloroplasts in the cell; KAM1/MUR3 that define the morphology of the Golgi apparatus as well as the composition of xyloglucans in the cell wall; NtWLIM1, which facilitates the emergence of actin cell structures; and ERD10, which is involved in the association of organelles within membranes and microfilaments and which seems to play a role that is involved in an organism's reaction to stress.
Sources: en.wikipedia.org
=== COVID-19 === The pharmacokinetic boosting property of ritonavir has been successfully repurposed for the treatment of COVID-19. It is co-packaged with nirmatrelvir, a SARS-CoV-2 main protease (3CLpro) inhibitor, under the brand name Paxlovid. In this combination regimen, ritonavir has no direct activity against SARS-CoV-2; rather, it inhibits the CYP3A4-mediated metabolism of nirmatrelvir, enhancing its systemic exposure to levels sufficient to halt viral replication. Clinical trials demonstrated that this combination significantly reduced the risk of hospitalization or death in high-risk patients when administered early (within five days of symptom onset), leading to emergency use authorizations and approvals by agencies such as the US Food and Drug Administration (FDA) and the World Health Organization (WHO).
== External links == Media related to Binge eating disorder at Wikimedia Commons Pull, Charles B (January 2004). "Binge eating disorder". Current Opinion in Psychiatry. 17 (1): 43–48. doi:10.1097/00001504-200401000-00008. Binge Eating Disorder on National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
== Droplet CCC == Droplet countercurrent chromatography (DCCC) was introduced in 1970 by Tanimura, Pisano, Ito, and Bowman. DCCC uses only gravity to move the mobile phase through the stationary phase which is held in long vertical tubes connected in series. In the descending mode, droplets of the denser mobile phase and sample are allowed to fall through the columns of the lighter stationary phase using only gravity. If a less-dense mobile phase is used it will rise through the stationary phase; this is called ascending mode. The eluent from one column is transferred to another; the more columns that are used, the more theoretical plates can be achieved. DCCC enjoyed some success with natural product separations but was largely eclipsed by the rapid development of high-speed countercurrent chromatography. The main limitation of DCCC is that flow rates are low, and poor mixing is achieved for most binary solvent systems.
=== Drug transport === South American cartels and Moroccan crime syndicates have maintained good relationships, and created trafficking networks to transport cargoes that involved thousands of containers through Moroccan ports since the 1980s. Due to the large waves of Moroccan immigration to the Netherlands and Belgium, beginning Moroccan traffickers were able to infiltrate the ports of Rotterdam and Antwerp, and criminal networks were eventually able to grow their influences over these port cities. In the 2000s, drug traffickers in these port-cities have changed the use of their hashish and cannabis routes for the use of cocaine trafficking to gain larger profits. A large part of these traffickers came from the north of Morocco, which explains their ease in expressing themselves in the Spanish language. With the arrival of new communication technologies, it was easier for these organisations to create and maintain new contacts, and networks were eventually established over three continents. The Moroccan mafia in the Netherlands and Belgium dominate the European market for cocaine, cannabis and synthetic drugs, alongside the Irish Mob, and the Italian (’Ndrangheta and Camorra), Serbian, and Albanian mafia. Moroccan gangs in Amsterdam, Utrecht, and Rotterdam have a firm foothold in importing cocaine from South America, particularly from Peru and Colombia, where Colombian cartels trust Dutch- and Belgian-Moroccan drug traffickers in Antwerp to receive and distribute these drugs.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.